Tech Company Financing Transactions

Fovea Pharmaceuticals Funding Round

Fovea Pharmaceuticals secured a $44 million Series B investment round on 12/13/2007. Backers included Forbion Capital Partners, Abingworth and Credit Agricole Private Equity.

Transaction Overview

Company Name
Fovea Pharmaceuticals
Announced On
12/13/2007
Transaction Type
Venture Equity
Amount
$44,000,000
Round
Series B
Investors

Forbion Capital Partners (Lead Investor) (Sander Slootweg)

Abingworth (Timothy Haines)

Credit Agricole Private Equity

GIMV

Sofinnova Ventures (Antoine Papiernik)

The Wellcome Trust

Proceeds Purpose
Fovea plans to use the proceeds from this financing to advance its clinical and preclinical pipeline and further develop its technology platform. In 2008, Fovea expects to advance its FOV1101 program for chronic allergic conjunctivitis into phase 2 clinical trials and to initiate phase 2 studies of its FOV2302 and FOV2301 programs for the treatment of respectively acute and diabetic macular edema. The company expects to bring its fourth drug candidate, FOV2501, a protein discovered by Pr Jose-Alain Sahel's team (Inserm-UPMC U 592), into clinical trials in the first half of 2009.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
17 rue Moreau
Paris, 75012
France
Phone
+33 (0)1 44 16 42 42
Website
www.fovea-pharma.com
Email Address
[email protected]
Overview
Fovea is dedicated to the discovery and development of INNOVATION in products for ocular diseases (retinal degeneration, glaucoma, dry eye, allergy and inflammation).
Profile
Fovea Pharmaceuticals LinkedIn Company Profile
Social Media
Fovea Pharmaceuticals Company Twitter Account
Company News
Fovea Pharmaceuticals News
Facebook
Fovea Pharmaceuticals on Facebook
YouTube
Fovea Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Bernard Gilly
  Bernard Gilly LinkedIn Profile  Bernard Gilly Twitter Account  Bernard Gilly News  Bernard Gilly on Facebook
Chief Financial Officer
Strategic Controller
  Strategic Controller LinkedIn Profile  Strategic Controller Twitter Account  Strategic Controller News  Strategic Controller on Facebook
Chief Medical Officer
Soraya Bekkali
  Soraya Bekkali LinkedIn Profile  Soraya Bekkali Twitter Account  Soraya Bekkali News  Soraya Bekkali on Facebook
Chief Operating Officer
Pierre Bélichard
  Pierre Bélichard LinkedIn Profile  Pierre Bélichard Twitter Account  Pierre Bélichard News  Pierre Bélichard on Facebook
VP - Operations
Gilles Litman
  Gilles Litman LinkedIn Profile  Gilles Litman Twitter Account  Gilles Litman News  Gilles Litman on Facebook

 

 

Browse more venture capital transactions:

Prev: 12/13/2007: Saladax Biomedical venture capital transaction
Next: 12/13/2007: Sitrion venture capital transaction

 

Share this article

 

Where The Data Comes From

Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.